诱导肿瘤、病毒特异细胞免疫及tetramer技术检测抗原特异CTL
摘要
目的
癌症免疫治疗的主要目的是诱导有效的抗肿瘤特异细胞毒T淋巴细胞(CTL)，而主要组织相容性复合物(MHC)Ⅰ类分子在一系列恶性肿瘤中往往低表达，不足以在体内引起有效的免疫应答。人癌症中的自身抗原是免疫系统识别的最普遍抗原，说明癌细胞源于宿主自身组织而非外源蛋白。识别自身抗原存在许多问题，如由于自身耐受难以引出抗肿瘤免疫。即使免疫系统能识别并与自身抗原反应，通常免疫力也不足以排斥肿瘤。
FasL是肿瘤坏死因子(TNF)蛋白家族的一个成员，组织学和流式细胞仪分析提示FasL表达细胞能引起局部中性粒细胞浸润，产生强烈的炎症，使肿瘤细胞受损，之后依赖CD8~+T淋巴细胞的抗肿瘤免疫，导致肿瘤细胞的清除。B16F10恶性黑色素瘤免疫原性极弱，因此是研究提高肿瘤免疫策略的良好模式。恶性黑色素瘤最具特色的抗原是非突变分化抗原，不仅表达于恶性黑色素瘤细胞，也表达于正常黑色素细胞，如糖蛋白100(gp100)，酪氨酸酶、酪氨酸酶相关蛋白(TRP)1和2、黑素A(Melan-A)。从这些抗原中选择3个有肿瘤排斥功能的抗原决定簇：TRP2、鼠糖蛋白100(mgp100)和它更具免疫源性的对应物人gp100(hgp100)。此外，还选择了2个在B16F10中表达的内生性病毒抗原决定簇恶性黑色素瘤抗原肽(mdm)、逆病毒包膜蛋白(p15E)，合成抗原肽，制作Tetramer。
MHC-Ⅰ类分子-肽四聚体复合物技术是近年牛津大学同美国STAN-FORD大学共同研制发明的。它可以通过荧光激活细胞分类仪(FACS)在单细胞水平直接检测抗原特异性CTL，并同时进行细胞定量。经放射并表达FasL的B16F10细胞皮下注射使鼠产生免疫，3周后野生型B16F10激发，保护鼠行tetramer分析。牛痘病毒不仅诱导体液免疫，且强烈地诱导细胞免疫。因此，为了提高免疫应答，部分保护鼠用含黑色素分化抗原的重组牛痘病毒(rVV)加强。体内抗原特异杀伤还用另一种新技术来检测。希望我们的观察能帮助确定新的肿瘤细胞表面标志物，提供一种刺激产生广谱抗肿瘤免疫的新途径。
实验方法
本实验用B16F10恶性黑色素瘤C57BL／6鼠模型。使用2种技术来检测免疫鼠中抗原特异CTL活性。
1) MHCⅠ类分子-肽-tetramer。选择5种相关肿瘤抗原决定簇，合成抗原肽，其氨基酸序列如下：mdm(Kb)：YAMIYRNL，p15E(Kb)：KSPWFTTL，trp-2(v)(K~b)：VYDFFVWL，trp-2(s)(K~b)：SVYDFFVWL hgp100(D~b)：KVPKNQDWL，mgp100(D~b)：EGSRNQDWL，制作相应tetramer：BirA生物素酶识别位点的MHC-H-2K~b或H-2D~b的胞外区、β2m的cDNA被克隆进入表达质粒，蛋白以包涵体形式在大肠杆菌(E.coli)中表达。重链、β2m和合成抗原肽在4℃含蛋白酶抑制剂的缓冲液中折叠，形成稳定的三分子复合物。浓缩后，复合物酶标生物素酰基化，由快速蛋白液相色谱(FPLC)按照分子量大小纯化。生物素酰基化蛋白单体与结合荧光素的细菌蛋白以4∶1摩尔比率混合。
2)体内杀伤分析。CFSE是一种分子探针染料，在488nm可激发绿色荧光，因此可通过流式细胞仪检测。树突状细胞(DC)如与荧光染料结合，可在引流淋巴结中被检出。DC与MHC-Ⅰ类分子抗原肽结合，可作为CTL的靶，如存在抗原特异CTL，结合抗原DC的特异杀伤就能在不同小鼠中被检测出来。结合CFSE的同源靶细胞(脾)加入相关抗原肽，尾静脉注入保护鼠，5～18小时采集鼠血或鼠脾，FACS分析。标记相关抗原肽的靶细胞由于被特异CTLs识别和杀伤，应该减少或消失。
将实验与对照鼠分成4组，施以不同处理因素：FasL，rVV(mgp100，NP)，FasL+rVV组，对照组，用以初次免疫激活。用自然鼠脾细胞与抗原肽(hgp100，Np)加强一次，行tetramer检测及体内杀伤实验。体外培养各组脾细胞建立CTL细胞系，共分两组，1组用hgp100刺激，末次刺激后一周用hgp100，mgp100两种tetramer检测，另1组分别用6种抗原肽刺激，末次刺激后行tetramer交叉检测。
实验结果
我们建立起一种tetramer与碘化丙啶(PI)相结合的技术。排除PI阳性细胞，有助于减少死细胞非特异染色，提高染色质量。重复多次实验，除一只rVVNP处理鼠作为阳性对照，脾脏中检出抗原特异CTL，其他各组血液、淋巴结、脾tetramer检测均阴性。我们共进行了5次杀伤实验，均难以解释。由于没能从鼠中得到足够细胞，标记CFSE、结合抗原肽的对照峰和相关峰都较低。血液标本出现双峰，脾脏检测出现单峰。与其他组相比，FasL+rVVgp100组，峰高明显降低，但无抗原特异性，因为对照峰与相关峰均降低。体外细胞培养，第1组中rVV处理细胞、FasL+rVVgp100处理细胞，tetramer检测，出现抗原特异CTL，hgp100、mgp100 tetramer检测均阳性，其它组阴性。第2组中FasL+rVVgp100处理细胞，出现tetramer交叉检测阳性，其它处理因素脾细胞检测阴性，提示在一些标本中存在非特异背景染色。
结论
1．tetramer技术能精确检测肿瘤抗原特异CTL。
2．FasL与rVVgp100两种处理因素联合能打破恶性黑色素瘤B16F10的自身耐受状态，产生抗原特异性CTL。
3．FasL与rVVgp100两种处理因素联合，可能诱导固有免疫，产生非特异性杀伤。
4．FasL与rVVgp100两种处理因素联合，能扩大免疫效应，产生抗原交叉反应。
5．小鼠免疫成功与否，与不同小鼠不同免疫状态及反应性有关。将来有必要扩大每组小鼠数量。
6．FACS检测体外培养细胞时，同时使用PI能去除死细胞干扰，提高染色质量。
7．细胞体外培养，末次刺激后两周tetramer检测达高峰。
8．本研究结果为研制肿瘤疫苗、制定肿瘤治疗策略提供了新思路。
The purpose of immunotherapy in cancer is to induce an effective anti-tumorspecific cytotoxic T lymphocytes (CTL) response, however, major histocompati-bility complex (MHC) class I is usually expressed at low levels by tumors andcant elicit effective immune responses. Self-antigens are the most common anti-gens that are recognized in human cancer. Immune responses to self-antigens aredifficult to induce because of self-tolerance. Even if the immune system recogni-zes and makes a response to self antigens, it is often too weak to reject thetumor.
FasL is a member of TNF protein family; expression of FasL can confer im-mune privilege to some organs, allowing them to kill infiltrating lymphocytes andinflammatory cells. However, the expression of FasL in a number of instancesprovokes an intense neutrophil infiltrating. Neutrophils expressing Fas can be at-tracted and activated by FasL to become cytotoxic. It is believed that this neu-trophil activation impairs tumor growth, then induces an adaptive immune re-sponse possibly mediated by CTLs. In this study we tested whether FasL ex-pressed by tumors is able to induce a CTL response. TheB16F10 melanomamodel was used because it is a poorly immunogenic tumor and thus a good modelto test strategies to enhance tumor immunity. The best-characterized melanomaantigens are the non-mutated differentiation antigens expressed in both melanomaand melanocytes: gp100, Tyrosinase, Tyrosinase-Related-Protein (TRP) 1 and2 and Melan-A. Three epitopes were chosen from these antigens known to be in-volved in the rejection of the tumor: murine gp100 (mgp100) and its more im-munogenic counterpart in human (hgp100) and TRP2. Furthermore twoepitopes from endogenous virus described to be expressed by B16F10 were alsochosen, peptides were synthesized and tetramers generated.
The MHC class I tetramer technology was recently developed by Oxford andStanford universities. It can quantify and analyze antigen specific CTL at a sin-gle cell level by FACS. Mice were immunized with irradiated B16F10 expressingFasL and then challenged with wild type B16F10. Protected mice were chosenfor tetramer analysis. To improve the response, protected mice were boostedwith recombinant vaccinia virus expressing the melanocyte differentiation anti-gens. It is known that vaccinia virus can strongly induce T cell-mediated immu-nity as well as humoral immune response. Furthermore, antigen specific killingwas measured in vivo using a novel technique. We hope our observations mayhelp for the definition of new cell surface tumor markers and may provide an ad-ditional route to stimulate a broader anti-tumor response.
Material and Methods
We used the B16F10 melanoma C57BL/6 model. Two techniques wereused to detect antigen-specific CTL activity in immunized mice: 1) MHC classI-peptide tetramers. The protein sequence of five relevant epitopes are as fol-lows: mdm(K~b):YAMIYRNL,p15E (K~b) : KSPWFTTL, trp-2 (v) (K~b): VYD-FFVWL,trp-2(s) (K~b) :SVYDFFVWL hgp100 (D~b) : KVPKNQDWL. Makingcorresponding tetramers :Briefly, the cDNA for the MHC class-I and beta 2 mi-croglobulin are cloned into expression plasmids, and protein expressed as inclu-sion bodies within E. coli. After solubilisation, the class I molecule,theβ2mand synthetic peptide are added in relatively large quantities(10-30mg) to abuffer solution containing protease inhibitors at 4℃, in which the formation of astable trimolecular complex can occur, after concentration, the complexes areenzymatically biotinylated and purified by size. Monomeric complexes may thenbe frozen for future use or immediately formed into tetramers around streptavidin-phycoerythrocin (SA-PE) conjugates. 2) In vivo killing assay: CFSE is a mo-lecular probe that emits green fluorescence at 488nm, thus can be detected byFACS. Combine with DC, it can be found in draining lymphatic nodes. It canbe a target for CTL if DC integrates with MHC class I Label syngeneic targetcells (Spleen)with CFSE and pulse with relevant peptides, then inject into pro- tected mice, bleed mice 5～18 hours later and perform FACS analysis of bloodsamples. Target cells labeled with the relevant peptide should disappear, as theywill be specifically killed by CTLs recognizing the peptide. Mice were dividedinto 4 groups for priming and boosting 1) B16F10-FasL followed by rVV(mgp100, NP), B16F10-FasL, rVV ,naive mice. Sometimes mice were alsoboosted with spleen cells loaded with peptides one week later, Tetramer stainingand vivo killing were performed. Spleen cells of the different groups are culturedto set up CTL lines. All cells were divided into two groups, one group was stim-ulated with hgp100 and tested by two kinds of tetramers: hgp100, mgp100 aweek later after final in vitro stimulation. The other six CTL lines were stimula-ted by six peptides and crisscross staining was performed after finial stimulation.
Results
We established a technique whereby tetramer staining was combined withPropidium iodide (PI). Excluding PI positive cells helped to reduce the unspe-cific staining of dead cells. No antigen specific CTLs were detected ex vivo, tes-ting blood, lymph nodes and spleens except a mouse that received vaccinia-NPand was stained with NP tetramer used as a positive control. We performed 5 vi-vo killings, which are difficult to interpret. Both the irrelevant control peak andthe relevant peak from the CFSE labeled and peptide-pulsed targets are verylow, as we did not retrieve enough cells from the mice. Blood testing yielded twopeaks, while spleen only one. Compare with other groups, the peaks of FasL+rVVgp100 disposing group are remarkably lower, but it is obvious that they arenot antigen specific killings as not only the peak with relevant peptide, but alsothe one with irrelevant peptide low. Tetramer positive CTLs were observed incell lines made from mice that received rVVgp100 and FasL+rVVgp100, testedby tetramer hgp100 and mgp100. All other groups are negative. The cell linemade from FasL+rVVgp100 mice also stained positive with irrelevant tetramer,while the other CTL lines negative, indicating that there is non-specific back-ground occurring in some of the samples.
Conclusions
1. Tetramer can detect antigen specific CTL accurately.
2. Combination of FasL and rVVgp100 can break self-tolerance to B16F10melanoma.
3. Combination of FasL and rVVgp100 induces possibly an innate immuneresponse, leading to unspecific killing.
4. Combination of FasL and rVVgp100 augments the overall immune reac-tion, leading to non-specific binding of irrelevant tetramer.
5. Success of immune response in mice varies among individual mice andtherefore bigger groups of mice need to be included in the future.
6. In combination with PI, the results of tetramer staining of CTL lines byFACS axe remarkably improved.
7. Best result was obtained after two weeks after final stimulation for theCTL lines.
8. Our observation and results will provide a basis to develop new anti-tumor vaccine and immunotherapy.
癌症免疫治疗的主要目的是诱导有效的抗肿瘤特异细胞毒T淋巴细胞(CTL)，而主要组织相容性复合物(MHC)Ⅰ类分子在一系列恶性肿瘤中往往低表达，不足以在体内引起有效的免疫应答。人癌症中的自身抗原是免疫系统识别的最普遍抗原，说明癌细胞源于宿主自身组织而非外源蛋白。识别自身抗原存在许多问题，如由于自身耐受难以引出抗肿瘤免疫。即使免疫系统能识别并与自身抗原反应，通常免疫力也不足以排斥肿瘤。
FasL是肿瘤坏死因子(TNF)蛋白家族的一个成员，组织学和流式细胞仪分析提示FasL表达细胞能引起局部中性粒细胞浸润，产生强烈的炎症，使肿瘤细胞受损，之后依赖CD8~+T淋巴细胞的抗肿瘤免疫，导致肿瘤细胞的清除。B16F10恶性黑色素瘤免疫原性极弱，因此是研究提高肿瘤免疫策略的良好模式。恶性黑色素瘤最具特色的抗原是非突变分化抗原，不仅表达于恶性黑色素瘤细胞，也表达于正常黑色素细胞，如糖蛋白100(gp100)，酪氨酸酶、酪氨酸酶相关蛋白(TRP)1和2、黑素A(Melan-A)。从这些抗原中选择3个有肿瘤排斥功能的抗原决定簇：TRP2、鼠糖蛋白100(mgp100)和它更具免疫源性的对应物人gp100(hgp100)。此外，还选择了2个在B16F10中表达的内生性病毒抗原决定簇恶性黑色素瘤抗原肽(mdm)、逆病毒包膜蛋白(p15E)，合成抗原肽，制作Tetramer。
MHC-Ⅰ类分子-肽四聚体复合物技术是近年牛津大学同美国STAN-FORD大学共同研制发明的。它可以通过荧光激活细胞分类仪(FACS)在单细胞水平直接检测抗原特异性CTL，并同时进行细胞定量。经放射并表达FasL的B16F10细胞皮下注射使鼠产生免疫，3周后野生型B16F10激发，保护鼠行tetramer分析。牛痘病毒不仅诱导体液免疫，且强烈地诱导细胞免疫。因此，为了提高免疫应答，部分保护鼠用含黑色素分化抗原的重组牛痘病毒(rVV)加强。体内抗原特异杀伤还用另一种新技术来检测。希望我们的观察能帮助确定新的肿瘤细胞表面标志物，提供一种刺激产生广谱抗肿瘤免疫的新途径。
实验方法
本实验用B16F10恶性黑色素瘤C57BL／6鼠模型。使用2种技术来检测免疫鼠中抗原特异CTL活性。
1) MHCⅠ类分子-肽-tetramer。选择5种相关肿瘤抗原决定簇，合成抗原肽，其氨基酸序列如下：mdm(Kb)：YAMIYRNL，p15E(Kb)：KSPWFTTL，trp-2(v)(K~b)：VYDFFVWL，trp-2(s)(K~b)：SVYDFFVWL hgp100(D~b)：KVPKNQDWL，mgp100(D~b)：EGSRNQDWL，制作相应tetramer：BirA生物素酶识别位点的MHC-H-2K~b或H-2D~b的胞外区、β2m的cDNA被克隆进入表达质粒，蛋白以包涵体形式在大肠杆菌(E.coli)中表达。重链、β2m和合成抗原肽在4℃含蛋白酶抑制剂的缓冲液中折叠，形成稳定的三分子复合物。浓缩后，复合物酶标生物素酰基化，由快速蛋白液相色谱(FPLC)按照分子量大小纯化。生物素酰基化蛋白单体与结合荧光素的细菌蛋白以4∶1摩尔比率混合。
2)体内杀伤分析。CFSE是一种分子探针染料，在488nm可激发绿色荧光，因此可通过流式细胞仪检测。树突状细胞(DC)如与荧光染料结合，可在引流淋巴结中被检出。DC与MHC-Ⅰ类分子抗原肽结合，可作为CTL的靶，如存在抗原特异CTL，结合抗原DC的特异杀伤就能在不同小鼠中被检测出来。结合CFSE的同源靶细胞(脾)加入相关抗原肽，尾静脉注入保护鼠，5～18小时采集鼠血或鼠脾，FACS分析。标记相关抗原肽的靶细胞由于被特异CTLs识别和杀伤，应该减少或消失。
将实验与对照鼠分成4组，施以不同处理因素：FasL，rVV(mgp100，NP)，FasL+rVV组，对照组，用以初次免疫激活。用自然鼠脾细胞与抗原肽(hgp100，Np)加强一次，行tetramer检测及体内杀伤实验。体外培养各组脾细胞建立CTL细胞系，共分两组，1组用hgp100刺激，末次刺激后一周用hgp100，mgp100两种tetramer检测，另1组分别用6种抗原肽刺激，末次刺激后行tetramer交叉检测。
实验结果
我们建立起一种tetramer与碘化丙啶(PI)相结合的技术。排除PI阳性细胞，有助于减少死细胞非特异染色，提高染色质量。重复多次实验，除一只rVVNP处理鼠作为阳性对照，脾脏中检出抗原特异CTL，其他各组血液、淋巴结、脾tetramer检测均阴性。我们共进行了5次杀伤实验，均难以解释。由于没能从鼠中得到足够细胞，标记CFSE、结合抗原肽的对照峰和相关峰都较低。血液标本出现双峰，脾脏检测出现单峰。与其他组相比，FasL+rVVgp100组，峰高明显降低，但无抗原特异性，因为对照峰与相关峰均降低。体外细胞培养，第1组中rVV处理细胞、FasL+rVVgp100处理细胞，tetramer检测，出现抗原特异CTL，hgp100、mgp100 tetramer检测均阳性，其它组阴性。第2组中FasL+rVVgp100处理细胞，出现tetramer交叉检测阳性，其它处理因素脾细胞检测阴性，提示在一些标本中存在非特异背景染色。
结论
1．tetramer技术能精确检测肿瘤抗原特异CTL。
2．FasL与rVVgp100两种处理因素联合能打破恶性黑色素瘤B16F10的自身耐受状态，产生抗原特异性CTL。
3．FasL与rVVgp100两种处理因素联合，可能诱导固有免疫，产生非特异性杀伤。
4．FasL与rVVgp100两种处理因素联合，能扩大免疫效应，产生抗原交叉反应。
5．小鼠免疫成功与否，与不同小鼠不同免疫状态及反应性有关。将来有必要扩大每组小鼠数量。
6．FACS检测体外培养细胞时，同时使用PI能去除死细胞干扰，提高染色质量。
7．细胞体外培养，末次刺激后两周tetramer检测达高峰。
8．本研究结果为研制肿瘤疫苗、制定肿瘤治疗策略提供了新思路。
The purpose of immunotherapy in cancer is to induce an effective anti-tumorspecific cytotoxic T lymphocytes (CTL) response, however, major histocompati-bility complex (MHC) class I is usually expressed at low levels by tumors andcant elicit effective immune responses. Self-antigens are the most common anti-gens that are recognized in human cancer. Immune responses to self-antigens aredifficult to induce because of self-tolerance. Even if the immune system recogni-zes and makes a response to self antigens, it is often too weak to reject thetumor.
FasL is a member of TNF protein family; expression of FasL can confer im-mune privilege to some organs, allowing them to kill infiltrating lymphocytes andinflammatory cells. However, the expression of FasL in a number of instancesprovokes an intense neutrophil infiltrating. Neutrophils expressing Fas can be at-tracted and activated by FasL to become cytotoxic. It is believed that this neu-trophil activation impairs tumor growth, then induces an adaptive immune re-sponse possibly mediated by CTLs. In this study we tested whether FasL ex-pressed by tumors is able to induce a CTL response. TheB16F10 melanomamodel was used because it is a poorly immunogenic tumor and thus a good modelto test strategies to enhance tumor immunity. The best-characterized melanomaantigens are the non-mutated differentiation antigens expressed in both melanomaand melanocytes: gp100, Tyrosinase, Tyrosinase-Related-Protein (TRP) 1 and2 and Melan-A. Three epitopes were chosen from these antigens known to be in-volved in the rejection of the tumor: murine gp100 (mgp100) and its more im-munogenic counterpart in human (hgp100) and TRP2. Furthermore twoepitopes from endogenous virus described to be expressed by B16F10 were alsochosen, peptides were synthesized and tetramers generated.
The MHC class I tetramer technology was recently developed by Oxford andStanford universities. It can quantify and analyze antigen specific CTL at a sin-gle cell level by FACS. Mice were immunized with irradiated B16F10 expressingFasL and then challenged with wild type B16F10. Protected mice were chosenfor tetramer analysis. To improve the response, protected mice were boostedwith recombinant vaccinia virus expressing the melanocyte differentiation anti-gens. It is known that vaccinia virus can strongly induce T cell-mediated immu-nity as well as humoral immune response. Furthermore, antigen specific killingwas measured in vivo using a novel technique. We hope our observations mayhelp for the definition of new cell surface tumor markers and may provide an ad-ditional route to stimulate a broader anti-tumor response.
Material and Methods
We used the B16F10 melanoma C57BL/6 model. Two techniques wereused to detect antigen-specific CTL activity in immunized mice: 1) MHC classI-peptide tetramers. The protein sequence of five relevant epitopes are as fol-lows: mdm(K~b):YAMIYRNL,p15E (K~b) : KSPWFTTL, trp-2 (v) (K~b): VYD-FFVWL,trp-2(s) (K~b) :SVYDFFVWL hgp100 (D~b) : KVPKNQDWL. Makingcorresponding tetramers :Briefly, the cDNA for the MHC class-I and beta 2 mi-croglobulin are cloned into expression plasmids, and protein expressed as inclu-sion bodies within E. coli. After solubilisation, the class I molecule,theβ2mand synthetic peptide are added in relatively large quantities(10-30mg) to abuffer solution containing protease inhibitors at 4℃, in which the formation of astable trimolecular complex can occur, after concentration, the complexes areenzymatically biotinylated and purified by size. Monomeric complexes may thenbe frozen for future use or immediately formed into tetramers around streptavidin-phycoerythrocin (SA-PE) conjugates. 2) In vivo killing assay: CFSE is a mo-lecular probe that emits green fluorescence at 488nm, thus can be detected byFACS. Combine with DC, it can be found in draining lymphatic nodes. It canbe a target for CTL if DC integrates with MHC class I Label syngeneic targetcells (Spleen)with CFSE and pulse with relevant peptides, then inject into pro- tected mice, bleed mice 5～18 hours later and perform FACS analysis of bloodsamples. Target cells labeled with the relevant peptide should disappear, as theywill be specifically killed by CTLs recognizing the peptide. Mice were dividedinto 4 groups for priming and boosting 1) B16F10-FasL followed by rVV(mgp100, NP), B16F10-FasL, rVV ,naive mice. Sometimes mice were alsoboosted with spleen cells loaded with peptides one week later, Tetramer stainingand vivo killing were performed. Spleen cells of the different groups are culturedto set up CTL lines. All cells were divided into two groups, one group was stim-ulated with hgp100 and tested by two kinds of tetramers: hgp100, mgp100 aweek later after final in vitro stimulation. The other six CTL lines were stimula-ted by six peptides and crisscross staining was performed after finial stimulation.
Results
We established a technique whereby tetramer staining was combined withPropidium iodide (PI). Excluding PI positive cells helped to reduce the unspe-cific staining of dead cells. No antigen specific CTLs were detected ex vivo, tes-ting blood, lymph nodes and spleens except a mouse that received vaccinia-NPand was stained with NP tetramer used as a positive control. We performed 5 vi-vo killings, which are difficult to interpret. Both the irrelevant control peak andthe relevant peak from the CFSE labeled and peptide-pulsed targets are verylow, as we did not retrieve enough cells from the mice. Blood testing yielded twopeaks, while spleen only one. Compare with other groups, the peaks of FasL+rVVgp100 disposing group are remarkably lower, but it is obvious that they arenot antigen specific killings as not only the peak with relevant peptide, but alsothe one with irrelevant peptide low. Tetramer positive CTLs were observed incell lines made from mice that received rVVgp100 and FasL+rVVgp100, testedby tetramer hgp100 and mgp100. All other groups are negative. The cell linemade from FasL+rVVgp100 mice also stained positive with irrelevant tetramer,while the other CTL lines negative, indicating that there is non-specific back-ground occurring in some of the samples.
Conclusions
1. Tetramer can detect antigen specific CTL accurately.
2. Combination of FasL and rVVgp100 can break self-tolerance to B16F10melanoma.
3. Combination of FasL and rVVgp100 induces possibly an innate immuneresponse, leading to unspecific killing.
4. Combination of FasL and rVVgp100 augments the overall immune reac-tion, leading to non-specific binding of irrelevant tetramer.
5. Success of immune response in mice varies among individual mice andtherefore bigger groups of mice need to be included in the future.
6. In combination with PI, the results of tetramer staining of CTL lines byFACS axe remarkably improved.
7. Best result was obtained after two weeks after final stimulation for theCTL lines.
8. Our observation and results will provide a basis to develop new anti-tumor vaccine and immunotherapy.
引文
1. Smyth MJ, Trapani A. Lymphocyte-mediated immunosurveillance of epithelial cancer? Trends Immunol. 2001,22:409-411
2. Marincoh FM, Jaffee EM, Hicklin Dj, et al. Escape of human solid tumours from T-cell recognition: molecular mechanism and functional significance. Adv Immunol. 2000,74:181-273
3. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003,111:639-647
4. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specificcytolytic T lymphocytes. J Exp Med. 1998, 188 : 1641-1650
5. Houghton AN. Cancer antigens:immune recognition of self and altered self. J Exp Med. 1994,180:1-4
6. Wibur BB, Roopa S, Jedd DW, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999,190 : 1717-1722
7. Saas, P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997, 99 : 1173 1178
8. O Connen J, Houston A, Bennett MW, et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2001,7:271 274
9. Shimizu M, Fontana A, Takeda Y, et al. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol. 1999, 162:7350 7357
10. Strebel A, Harr T, Bachmann F, et al. Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry. 2001,43(2) : 126-133
11. Anna Katharina S, Awen G,Emma J, et al. Fas ligand breaks tolerance to self-antigen and induces t-mor immunity mediated by antibodies. Cancer Cell.2002,2:1-9
12. Altman JD ,Moss PAH, Goulder PJR,et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996,274:94-96
13. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-re-lated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997,185:453-459
14. Julia S, Jurgen B, Kerstin S, etal. Genetic immunization of mice with human tyrosin-related protein 2:implication for immunotherapy of melanoma. Int J Cancer. 2000,86:89-94
15. Marco WJs, Schreurs AO, Eggert A J, et al. Dendritic cells break tolerance and induce protective immunity against a melanoeyte differentiation antigen in an autologous melanoma model. Cancer Research. 2000,60:6995-7001
16. Rejean L, Richard ER, Royal ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC Class I and Class Ⅱ epitope from antigen glycpprotein 100. J of Immuno. 2001, 167: 4758-4764
17. Sadovnikova E,Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Pro Natl Aead SCi USA. 1996,93 : 13114-13118
18. Herbert JZ, Donna PL, Mark ED, et al. High avidity CTLs for two self-anti-gens demonstrate superior in vitro and in vivo antitumor efficacy. Immunology. 1999,162:989-994
19. Willem WO, Marc RT, Steven EF,et al. Tumor regression and autoimmunity after reversal of a functional toleranct state of self-reactive CD8~+ T cells. The Journal of Experimental Medicine. 2003,198:569-580
20．钱丽，钱关祥．重组牛痘病毒介导的微小基因表达产物在真核细胞中的抗原呈递效率．生物化学与生物物理学报．2002，34：719-724
21. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000 ,21 ;243: 147-154
22. David SR, Ian FH, Joanne ML, Dendritic cell elimination as an assay of eytotoxie T lymphocyte activity in vivo. J of Immunol Methods. 2000,246:109-117
23. Choi EM, Palmowski M, Chen J. The use of chimeric A2Kb tetramers to monitor HLA A2 immune responses in HIA A2 transgenic mice. J Immunol Methods. 2002, 268:35-41
24. Paul K, Vincenzo C, P. Rod D. Tracking T cells with tetramers: new tales from new tools. Nature Reviews/Immunology. 2002,2: 263-272
25．龚非力主编．医学免疫学．科学出版社．2000，P361
26. Overwijk WW, Tsung A,Irvine KR,et al. Gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive, tumoricidal T ceils using high-affinity, altered peptide ligand. J Exo Med. 1998,188:277-286
27. Rongfu W, Ettore A, Yutaka K, et al. Identification of trp-2 as a human antigen recognized by cytotoxic T lymphoeytes. J Exp Med. 1996,184: 2207-2216
28. Moss B. Vaccinia Virus:A tool for research and vaccine dvelopment. Science. 1991,252:1662-1667
29. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000, 407:789-795
30. Motomu S, Adriano F, Yasutaka T, et al. Fas/Apo-1 (CD95)-Mediated Apoptosis of Neutrophils with Fas Ligand (CD95L)-Expressing Tumors Is Crucial for Induction of Inflammation by Neutrophilic Polymorphonuclear Leuko cytes Associated with Antitumor Immunity. Cellular Immunology. 2001, 207: 41-48
31. Stephan E, Joachim H, Peter A, et al. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med. 1997,185: 1241-1252
32. Schreurs MWJ, Eggert AAO, Punt CJA, et al. Dentric cells based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncogen. 2000,11:1-17
1. Stinchcomhe, JC, Bossi G, Booth S, et al. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001, 15:751-761
2. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J. Immumol Methods. 2002,268: 21-28
3. McMichael A J, Ting A, Zweerink HI, et al. HLA restriction of cell-media-ted lysis of infuenza virus-infected human cells. Nature. 1977, 270: 524-526
4. Charles AJ, Paul T, Mark W, et al. Immunobiology⑤2000. The importance of immunological memory in fixing adaotive immunity in the genome, 605～606
5. Krausa P, Barouch D, Bodmer JG, et al. Radid characterization of HLA Class Ⅰ alleles by gene mapping using ARMS PCR. Eur Immunogenet. 1995,22: 283-287
6. Lang KS, Moris A, Gouttefangeas C, et al. High frequency of human cyto-megalovirus (HCMV)-specific CD8~+ T cells detected in a healthy CMV-se-ropositive donor. Cell Mol Life Sci. 2002, 59:1076-1080
7. Komatsu H, Sierro S, V Cuero A, et al. Population analysis of antivinal T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol. 2003,134(1): 9-12
8. Falco DA, Nepomuceno RR, Krams SM, et al. Identification of Epstein-Barr virus-specific CD8~+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation. 2002,74 (4): 501-510
9. Annels NE, Callan MF, Tan L, et al. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J Immunol. 2000,165:4831-4841
10. Nicola EA, Margaret FCC, Linda T, et al. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J of Immunol. 2000, 165: 4831 4841
11. Schmittel A, Keilholz U, Bauer S, et al. Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J Immunol Methods. 2001 ,247(1-2) :17-24
12. Altman JD, Moss PAH, Geulder P, et al. Direct visualization and phenotypic analysis of virus-speciflc T lymphocytes in HIV-infected individuals. Science .1996,274:94-96
13. Trojan A, Urosevic M, Hummerjohann J, et al. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immuno ther. 2003 ,26 (1):41-46
14. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigenspeci c cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998, 8 : 413-416
15. Geraldine MAG, Mark RW, Victor A. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD81 T ymphocytes in healthy seropositive donors. J of Virology. 2000,74:8140-8150
16. Carlsson B, Cheng WS, Totterman TH, et al. Ex vivo stimulation of cytomegaloviros (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. British Journal of Haematology. 2003,121:428
17. Bachmann MF, Barner M, Viola A, et al. Distinct kinetics of cytokine production and cytolysis in effeetor and memory T cells after viral infection. Eur J Immunol. 1999 ,29:291-299
18. Lang KS, Moris A, Gouttefangeas C, et al. High frequency of human cytomegalovirus (HCMV)-specific CD8~+ T cells detected in a healthy CMV-se-ropositive donor. Cell Sol Life Sci. 2002 ,59 (6) : 1076-1080
19. Holmberg K, Mariathasan S, Ohteki T, et al. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol. 2003,171:2427-2434
20. Salio M, Valitutti S, Lanzavecchia A. Agonist-induced T 'cell receptor downregulation: molecular requirements and dissociation from T cell activation. Eur J Immunol. 1997 ,27 : 1769-1773
21. Weiss, A. T cell antigen receptor signal transduction: a tale of tails and cy- toplasmic protein-tyrosine kinases. Cell. 1993,73:209-212
22. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996,273:104-106
23. Zeling C,, Hidehiro K, Anders B, et al. Requirements for Peptide-induced T Cell Receptor Downregulation on Naive CD8 T Cells. J. Exp. Med. 1997, 185:641-65124. Coombs D, Kalergis AM, Nathenson SG,et al. Activated TCRs remain marked for internalization after dissociation from pMHC. Nat Immunol. 2002 ,3:926-931
24. Cooms D, Kalergis AM, Nathenson SG, et al. Activated TCRs remain marked for internalization after dissociation from pMHC. Nat Immunol. 2002,3:926-931
1. Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994,152:3904-3912
2. Kondo A, Sidney J, Southwood S, et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol. 1995, 155:4307-4312
3. Sigal LJ, Goebel P, Wylie DE. Db-binding peptides from influenza virus: effect of non-anchor residues on stability and mmunodominance. Mol Immunol. 1995,32:623-632
4. Charles Jr, Paul T, Mark, W, et al. Immunobiology⑤. Acquired immune deficiency syndrome, 2001,459
5. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1996,274:94-96
6. Ogg GS, Dunbar PR, Cerundolo V, et al. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer. 2000,82 : 1058-1062
7. Trojan A, Urosevic M, Hummerjohann J , et al. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immunother. 2003 ,26 (1):41-46
8. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994,152(1) :163-175
9. Franziska L, Ana LVC, Maria K, et al. Studies of human antiviral CD8~+ lymphocytes using class I peptide tetramers. Rev Med Virol. 2001,11:11-22
10. Zhang C, Cornette J L, Delisi C. Consistency in structural energeties of protein folding and peptide recognition. Protein Science. 1997, 6: 1057-1064.
11. Schueler-Furman, O, Altuvia Y, Sette A, et al. Structure-based prediction of binding peptides to MHC class Ⅰ molecules: application to a broad range of MHC alleles. Protein Sci. 2000, 9: 1838-1846
12. Brusic V, Schnbach C, Takiguchi M, et al. Application of genetic search in derivation of matrix models of peptide binding to MHC molecules. Ismb. 1997, 5: 75-83
13. Borras-Cuesta F, Golvano J, Garcia-Granero M, et al. Specific and general HLA-DR binding motifs: comparison of algorithms. Hum Immunol. 2000, 61: 266-278
1. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J Immunol Methods. 2002,268:21-28
2. McMichael AT, O' Callaghan CA. A new look at T cells. J Exp Med. 1998, 187 : 1367-1371
3. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infectod individuals. Science. 1996,274:94-96
4. Ogg GS, McMichael AJ. HlA-pepfide tetrameric complexes. Current Opinion in Immunology. 1998,10:393-396
5. Franziska L, Ana LVC, Maria K, et al. Studies of human antiviral CD8~+ lymphocyte using class I peptide tetramers. Rev Med Virol. 2001,11 : 11-12
1. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J Immumol Methods. 2002,268:21-28
2. McMichael AJ, Ting A, Zweerink HJ, et al. HLA restriction of cell-mediated lysis of infuenza virus-infected human cells. Nature. 1977, 270 : 524-526
3. Zinkernagel RM, Doherty PC. Restriction of an in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within asyngeneic or semiallogeneic system. Nature. 1974,248 : 701-702
4. Dawson H, Collins G, Pyle et al. The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev. 2004 ,125(2) :107-10
5. Xiaoning Xu, Marco AP, Nan Chen,et al. A novel approach to antigen-spe-cific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity. 2001, 14:591-602
6. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigen speci? c cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998, 8 : 413-416
7. Erard F, Wild MT, Garcia SJ, et al. Switch of CD8T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science. 1993, 260 : 1805-1805
8. Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8~+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods. 2002,268:9-19
9. Leehner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000, 191: 1499-1512
10. Ehl S, Homhach J, Aichele P, et al. Bystander activation of cytotoxie T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med. 1997,185 : 1241-1251
11. Willcox BE, Gao GF, Wyer JR, et al. TCR binding to peptide-MHC stabilizes a fexible recognition interface. Immunity. 1999, 10:357-365
12. Wyer JR, Wilcox BE, Gao GF, et al. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. Immunity. 1999, 10: 219-225
13. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1996,274:94-96
14. Sakai JA, Nagai M, Brennan MB, et al. In vitro spontaneous lymphoprolfferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease:predominant expansion of CD8 (+) T cells. Blood. 98: 1506-1511
15. Kaech SM, Ahmed R. Memory CD8~+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001,2:415-422
16. Oxenius A, Gunthard HF, Hirschel B,et al. Direct ex vivo analysis reveals distinct photypic patterns of HIV-specific CD8 (+)T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol. 2001, 31:1115-1121
17. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001,410 : 106-111
18. OHerrin SM, Slansky JE, Tang Q,et al. Antigen-specific blockade oft cells in vivo using dimeric MHC peptide. J Immunol. 2001,167(5) :2555-2560
19. Male R, Wang B, Schooler W, et al. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001,167(7) :3708-3714
20. Levy R . A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol. 2000, 37 : 43-46
21. Ogg GS, Dunbar PR, Cerundolo V, et al. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer. 2000,82 : 1058-1062
22. Robert B, Guillaume P, Luescher I, et al. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol. 2000, 30:3165-3170
23. Crawford F, Kozono H, White J, et al. Detection of antigen-specific T cells with multivalent soluble class Ⅱ MHC covalent peptide complexes. Immunity. 1998, 8:675-682
24. Kwok WW, Liu AW, Novak EJ, et al. HLA-DQ tetramers identify epitopespecific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol. 2000, 164:4244-4249
25. Novak EJ, Liu AW, Nepom GT,et al. MHC class Ⅱ tetramers identify peptide-specific human CD4 (+) T cells proliferating in response to infuenza A antigen. J Clin Invest. 1999, 104:R63-R67
26. Buckner JH, Holzer U, Novak EJ, et al. Defining antigen-specific responses with human MHC class Ⅱ tetramers. J Allergy Clin Immunol. 2002, 110: 199-208
27. Baumgarth N, Roederer M. A practical approach to muhicolor flow cytometry for immunophenotyping. J Immunol Methods. 2000,243 (1-2) :77-97
2. Marincoh FM, Jaffee EM, Hicklin Dj, et al. Escape of human solid tumours from T-cell recognition: molecular mechanism and functional significance. Adv Immunol. 2000,74:181-273
3. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003,111:639-647
4. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specificcytolytic T lymphocytes. J Exp Med. 1998, 188 : 1641-1650
5. Houghton AN. Cancer antigens:immune recognition of self and altered self. J Exp Med. 1994,180:1-4
6. Wibur BB, Roopa S, Jedd DW, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999,190 : 1717-1722
7. Saas, P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997, 99 : 1173 1178
8. O Connen J, Houston A, Bennett MW, et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2001,7:271 274
9. Shimizu M, Fontana A, Takeda Y, et al. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol. 1999, 162:7350 7357
10. Strebel A, Harr T, Bachmann F, et al. Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry. 2001,43(2) : 126-133
11. Anna Katharina S, Awen G,Emma J, et al. Fas ligand breaks tolerance to self-antigen and induces t-mor immunity mediated by antibodies. Cancer Cell.2002,2:1-9
12. Altman JD ,Moss PAH, Goulder PJR,et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996,274:94-96
13. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-re-lated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997,185:453-459
14. Julia S, Jurgen B, Kerstin S, etal. Genetic immunization of mice with human tyrosin-related protein 2:implication for immunotherapy of melanoma. Int J Cancer. 2000,86:89-94
15. Marco WJs, Schreurs AO, Eggert A J, et al. Dendritic cells break tolerance and induce protective immunity against a melanoeyte differentiation antigen in an autologous melanoma model. Cancer Research. 2000,60:6995-7001
16. Rejean L, Richard ER, Royal ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC Class I and Class Ⅱ epitope from antigen glycpprotein 100. J of Immuno. 2001, 167: 4758-4764
17. Sadovnikova E,Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Pro Natl Aead SCi USA. 1996,93 : 13114-13118
18. Herbert JZ, Donna PL, Mark ED, et al. High avidity CTLs for two self-anti-gens demonstrate superior in vitro and in vivo antitumor efficacy. Immunology. 1999,162:989-994
19. Willem WO, Marc RT, Steven EF,et al. Tumor regression and autoimmunity after reversal of a functional toleranct state of self-reactive CD8~+ T cells. The Journal of Experimental Medicine. 2003,198:569-580
20．钱丽，钱关祥．重组牛痘病毒介导的微小基因表达产物在真核细胞中的抗原呈递效率．生物化学与生物物理学报．2002，34：719-724
21. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000 ,21 ;243: 147-154
22. David SR, Ian FH, Joanne ML, Dendritic cell elimination as an assay of eytotoxie T lymphocyte activity in vivo. J of Immunol Methods. 2000,246:109-117
23. Choi EM, Palmowski M, Chen J. The use of chimeric A2Kb tetramers to monitor HLA A2 immune responses in HIA A2 transgenic mice. J Immunol Methods. 2002, 268:35-41
24. Paul K, Vincenzo C, P. Rod D. Tracking T cells with tetramers: new tales from new tools. Nature Reviews/Immunology. 2002,2: 263-272
25．龚非力主编．医学免疫学．科学出版社．2000，P361
26. Overwijk WW, Tsung A,Irvine KR,et al. Gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive, tumoricidal T ceils using high-affinity, altered peptide ligand. J Exo Med. 1998,188:277-286
27. Rongfu W, Ettore A, Yutaka K, et al. Identification of trp-2 as a human antigen recognized by cytotoxic T lymphoeytes. J Exp Med. 1996,184: 2207-2216
28. Moss B. Vaccinia Virus:A tool for research and vaccine dvelopment. Science. 1991,252:1662-1667
29. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000, 407:789-795
30. Motomu S, Adriano F, Yasutaka T, et al. Fas/Apo-1 (CD95)-Mediated Apoptosis of Neutrophils with Fas Ligand (CD95L)-Expressing Tumors Is Crucial for Induction of Inflammation by Neutrophilic Polymorphonuclear Leuko cytes Associated with Antitumor Immunity. Cellular Immunology. 2001, 207: 41-48
31. Stephan E, Joachim H, Peter A, et al. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med. 1997,185: 1241-1252
32. Schreurs MWJ, Eggert AAO, Punt CJA, et al. Dentric cells based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncogen. 2000,11:1-17
1. Stinchcomhe, JC, Bossi G, Booth S, et al. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001, 15:751-761
2. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J. Immumol Methods. 2002,268: 21-28
3. McMichael A J, Ting A, Zweerink HI, et al. HLA restriction of cell-media-ted lysis of infuenza virus-infected human cells. Nature. 1977, 270: 524-526
4. Charles AJ, Paul T, Mark W, et al. Immunobiology⑤2000. The importance of immunological memory in fixing adaotive immunity in the genome, 605～606
5. Krausa P, Barouch D, Bodmer JG, et al. Radid characterization of HLA Class Ⅰ alleles by gene mapping using ARMS PCR. Eur Immunogenet. 1995,22: 283-287
6. Lang KS, Moris A, Gouttefangeas C, et al. High frequency of human cyto-megalovirus (HCMV)-specific CD8~+ T cells detected in a healthy CMV-se-ropositive donor. Cell Mol Life Sci. 2002, 59:1076-1080
7. Komatsu H, Sierro S, V Cuero A, et al. Population analysis of antivinal T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol. 2003,134(1): 9-12
8. Falco DA, Nepomuceno RR, Krams SM, et al. Identification of Epstein-Barr virus-specific CD8~+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation. 2002,74 (4): 501-510
9. Annels NE, Callan MF, Tan L, et al. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J Immunol. 2000,165:4831-4841
10. Nicola EA, Margaret FCC, Linda T, et al. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J of Immunol. 2000, 165: 4831 4841
11. Schmittel A, Keilholz U, Bauer S, et al. Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J Immunol Methods. 2001 ,247(1-2) :17-24
12. Altman JD, Moss PAH, Geulder P, et al. Direct visualization and phenotypic analysis of virus-speciflc T lymphocytes in HIV-infected individuals. Science .1996,274:94-96
13. Trojan A, Urosevic M, Hummerjohann J, et al. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immuno ther. 2003 ,26 (1):41-46
14. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigenspeci c cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998, 8 : 413-416
15. Geraldine MAG, Mark RW, Victor A. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD81 T ymphocytes in healthy seropositive donors. J of Virology. 2000,74:8140-8150
16. Carlsson B, Cheng WS, Totterman TH, et al. Ex vivo stimulation of cytomegaloviros (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. British Journal of Haematology. 2003,121:428
17. Bachmann MF, Barner M, Viola A, et al. Distinct kinetics of cytokine production and cytolysis in effeetor and memory T cells after viral infection. Eur J Immunol. 1999 ,29:291-299
18. Lang KS, Moris A, Gouttefangeas C, et al. High frequency of human cytomegalovirus (HCMV)-specific CD8~+ T cells detected in a healthy CMV-se-ropositive donor. Cell Sol Life Sci. 2002 ,59 (6) : 1076-1080
19. Holmberg K, Mariathasan S, Ohteki T, et al. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol. 2003,171:2427-2434
20. Salio M, Valitutti S, Lanzavecchia A. Agonist-induced T 'cell receptor downregulation: molecular requirements and dissociation from T cell activation. Eur J Immunol. 1997 ,27 : 1769-1773
21. Weiss, A. T cell antigen receptor signal transduction: a tale of tails and cy- toplasmic protein-tyrosine kinases. Cell. 1993,73:209-212
22. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996,273:104-106
23. Zeling C,, Hidehiro K, Anders B, et al. Requirements for Peptide-induced T Cell Receptor Downregulation on Naive CD8 T Cells. J. Exp. Med. 1997, 185:641-65124. Coombs D, Kalergis AM, Nathenson SG,et al. Activated TCRs remain marked for internalization after dissociation from pMHC. Nat Immunol. 2002 ,3:926-931
24. Cooms D, Kalergis AM, Nathenson SG, et al. Activated TCRs remain marked for internalization after dissociation from pMHC. Nat Immunol. 2002,3:926-931
1. Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994,152:3904-3912
2. Kondo A, Sidney J, Southwood S, et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol. 1995, 155:4307-4312
3. Sigal LJ, Goebel P, Wylie DE. Db-binding peptides from influenza virus: effect of non-anchor residues on stability and mmunodominance. Mol Immunol. 1995,32:623-632
4. Charles Jr, Paul T, Mark, W, et al. Immunobiology⑤. Acquired immune deficiency syndrome, 2001,459
5. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1996,274:94-96
6. Ogg GS, Dunbar PR, Cerundolo V, et al. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer. 2000,82 : 1058-1062
7. Trojan A, Urosevic M, Hummerjohann J , et al. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immunother. 2003 ,26 (1):41-46
8. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994,152(1) :163-175
9. Franziska L, Ana LVC, Maria K, et al. Studies of human antiviral CD8~+ lymphocytes using class I peptide tetramers. Rev Med Virol. 2001,11:11-22
10. Zhang C, Cornette J L, Delisi C. Consistency in structural energeties of protein folding and peptide recognition. Protein Science. 1997, 6: 1057-1064.
11. Schueler-Furman, O, Altuvia Y, Sette A, et al. Structure-based prediction of binding peptides to MHC class Ⅰ molecules: application to a broad range of MHC alleles. Protein Sci. 2000, 9: 1838-1846
12. Brusic V, Schnbach C, Takiguchi M, et al. Application of genetic search in derivation of matrix models of peptide binding to MHC molecules. Ismb. 1997, 5: 75-83
13. Borras-Cuesta F, Golvano J, Garcia-Granero M, et al. Specific and general HLA-DR binding motifs: comparison of algorithms. Hum Immunol. 2000, 61: 266-278
1. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J Immunol Methods. 2002,268:21-28
2. McMichael AT, O' Callaghan CA. A new look at T cells. J Exp Med. 1998, 187 : 1367-1371
3. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infectod individuals. Science. 1996,274:94-96
4. Ogg GS, McMichael AJ. HlA-pepfide tetrameric complexes. Current Opinion in Immunology. 1998,10:393-396
5. Franziska L, Ana LVC, Maria K, et al. Studies of human antiviral CD8~+ lymphocyte using class I peptide tetramers. Rev Med Virol. 2001,11 : 11-12
1. Xiaoning Xu, Gavin RS. MHC/peptide tetramer-based studies of T cell function. J Immumol Methods. 2002,268:21-28
2. McMichael AJ, Ting A, Zweerink HJ, et al. HLA restriction of cell-mediated lysis of infuenza virus-infected human cells. Nature. 1977, 270 : 524-526
3. Zinkernagel RM, Doherty PC. Restriction of an in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within asyngeneic or semiallogeneic system. Nature. 1974,248 : 701-702
4. Dawson H, Collins G, Pyle et al. The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev. 2004 ,125(2) :107-10
5. Xiaoning Xu, Marco AP, Nan Chen,et al. A novel approach to antigen-spe-cific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity. 2001, 14:591-602
6. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigen speci? c cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998, 8 : 413-416
7. Erard F, Wild MT, Garcia SJ, et al. Switch of CD8T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science. 1993, 260 : 1805-1805
8. Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8~+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods. 2002,268:9-19
9. Leehner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000, 191: 1499-1512
10. Ehl S, Homhach J, Aichele P, et al. Bystander activation of cytotoxie T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med. 1997,185 : 1241-1251
11. Willcox BE, Gao GF, Wyer JR, et al. TCR binding to peptide-MHC stabilizes a fexible recognition interface. Immunity. 1999, 10:357-365
12. Wyer JR, Wilcox BE, Gao GF, et al. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. Immunity. 1999, 10: 219-225
13. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1996,274:94-96
14. Sakai JA, Nagai M, Brennan MB, et al. In vitro spontaneous lymphoprolfferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease:predominant expansion of CD8 (+) T cells. Blood. 98: 1506-1511
15. Kaech SM, Ahmed R. Memory CD8~+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001,2:415-422
16. Oxenius A, Gunthard HF, Hirschel B,et al. Direct ex vivo analysis reveals distinct photypic patterns of HIV-specific CD8 (+)T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol. 2001, 31:1115-1121
17. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001,410 : 106-111
18. OHerrin SM, Slansky JE, Tang Q,et al. Antigen-specific blockade oft cells in vivo using dimeric MHC peptide. J Immunol. 2001,167(5) :2555-2560
19. Male R, Wang B, Schooler W, et al. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001,167(7) :3708-3714
20. Levy R . A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol. 2000, 37 : 43-46
21. Ogg GS, Dunbar PR, Cerundolo V, et al. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer. 2000,82 : 1058-1062
22. Robert B, Guillaume P, Luescher I, et al. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol. 2000, 30:3165-3170
23. Crawford F, Kozono H, White J, et al. Detection of antigen-specific T cells with multivalent soluble class Ⅱ MHC covalent peptide complexes. Immunity. 1998, 8:675-682
24. Kwok WW, Liu AW, Novak EJ, et al. HLA-DQ tetramers identify epitopespecific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol. 2000, 164:4244-4249
25. Novak EJ, Liu AW, Nepom GT,et al. MHC class Ⅱ tetramers identify peptide-specific human CD4 (+) T cells proliferating in response to infuenza A antigen. J Clin Invest. 1999, 104:R63-R67
26. Buckner JH, Holzer U, Novak EJ, et al. Defining antigen-specific responses with human MHC class Ⅱ tetramers. J Allergy Clin Immunol. 2002, 110: 199-208
27. Baumgarth N, Roederer M. A practical approach to muhicolor flow cytometry for immunophenotyping. J Immunol Methods. 2000,243 (1-2) :77-97